CURIS INC
CRISDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
Ibrutinib Phase 2 Est. Readout
Primary completion for Ibrutinib trial (NCT03328078) in Relapsed Hematologic Malignancy
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How CRIS's past catalysts played out
CUDC-907
Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Emavusertib
Acute Myelogenous Leukemia
Ibrutinib
Relapsed Hematologic Malignancy
Zanubrutinib
Chronic Lymphocytic Leukemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CUDC-907 | Phase 2 | Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations | - | - |
Emavusertib | Phase 2 | Acute Myelogenous Leukemia | - | - |
Ibrutinib | Phase 2 | Relapsed Hematologic Malignancy | - | - |
Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CURIS INC's drug pipeline?→
CatalystAlert tracks 4 drug candidates in CURIS INC's (CRIS) pipeline across Phase 2. Its lead program is CUDC-907 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CURIS INC's next FDA catalyst?→
CURIS INC's (CRIS) next tracked catalyst is a Earnings expected August 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CRIS biotech catalysts?→
Add CRIS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CURIS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.